Periurethral injection of Bulkamid® for neurogenic vs. non-neurogenic female patients with stress urinary incontinence.

IF 1.2

The French journal of urology Pub Date : 2026-10-01 Epub Date: 2026-03-12 DOI:10.1016/j.fjurol.2026.103097

Mélanie Lepretre, Brice Faurie, Camille Haudebert, Claire Richard, Alexandre Dubois, Amaury Facque, Juliette Hascoet, Benoit Peyronnet

{"title":"Periurethral injection of Bulkamid® for neurogenic vs. non-neurogenic female patients with stress urinary incontinence.","authors":"Mélanie Lepretre, Brice Faurie, Camille Haudebert, Claire Richard, Alexandre Dubois, Amaury Facque, Juliette Hascoet, Benoit Peyronnet","doi":"10.1016/j.fjurol.2026.103097","DOIUrl":null,"url":null,"abstract":"Introduction: Data on bulking agents for stress urinary incontinence (SUI) in neurogenic patients remain limited, especially regarding polyacrylamide hydrogel (PAHG, Bulkamid®), now commonly used. This study evaluates the efficacy, safety, and tolerability of Bulkamid® in neurogenic women with SUI.Methods: From January 2020 to January 2025, we prospectively analyzed women undergoing periurethral Bulkamid® injections at a single center. Outcomes in neurogenic patients were compared to those without neurological disease. All procedures were performed outpatient under local anesthesia.Results: Fifteen neurogenic and 91 non-neurogenic women underwent treatment. Among neurogenic patients, 73.3% (11/15) reported improvement at 3 months (PGI-I). Four experienced transient acute urinary retention (27%). Self-catheterization was required in 3 patients; 2 remained unchanged post-procedure, and 1 improved. After a median 7-month follow-up, 66.7% of neurogenic patients remained dry or showed improvement. Complication rates were comparable between groups (20 vs. 27%, P=0.50). Treatment efficacy at 3 months was also similar (66.7% neurogenic vs. 63.3% non-neurogenic improved or very much improved; P=0.88).Conclusion: Bulkamid® shows comparable safety and efficacy in neurogenic and non-neurogenic women with SUI. However, benefits in patients performing self-catheterization remain uncertain and warrant further investigation.Level of evidence: 4: ","PeriodicalId":516865,"journal":{"name":"The French journal of urology","volume":" ","pages":"103097"},"PeriodicalIF":1.2000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The French journal of urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.fjurol.2026.103097","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/12 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Data on bulking agents for stress urinary incontinence (SUI) in neurogenic patients remain limited, especially regarding polyacrylamide hydrogel (PAHG, Bulkamid®), now commonly used. This study evaluates the efficacy, safety, and tolerability of Bulkamid® in neurogenic women with SUI.

Methods: From January 2020 to January 2025, we prospectively analyzed women undergoing periurethral Bulkamid® injections at a single center. Outcomes in neurogenic patients were compared to those without neurological disease. All procedures were performed outpatient under local anesthesia.

Results: Fifteen neurogenic and 91 non-neurogenic women underwent treatment. Among neurogenic patients, 73.3% (11/15) reported improvement at 3 months (PGI-I). Four experienced transient acute urinary retention (27%). Self-catheterization was required in 3 patients; 2 remained unchanged post-procedure, and 1 improved. After a median 7-month follow-up, 66.7% of neurogenic patients remained dry or showed improvement. Complication rates were comparable between groups (20 vs. 27%, P=0.50). Treatment efficacy at 3 months was also similar (66.7% neurogenic vs. 63.3% non-neurogenic improved or very much improved; P=0.88).

Conclusion: Bulkamid® shows comparable safety and efficacy in neurogenic and non-neurogenic women with SUI. However, benefits in patients performing self-catheterization remain uncertain and warrant further investigation.

Level of evidence: 4:

查看原文本刊更多论文

尿道周围注射Bulkamid®治疗神经源性与非神经源性女性压力性尿失禁。

导读：关于神经源性患者压力性尿失禁（SUI）的填充剂的数据仍然有限，特别是目前常用的聚丙烯酰胺水凝胶（PAHG, Bulkamid®）。本研究评估Bulkamid®在神经源性SUI女性患者中的疗效、安全性和耐受性。方法：从2020年1月到2025年1月，我们前瞻性地分析了在单一中心接受尿道周围注射Bulkamid®的女性。神经源性患者与无神经系统疾病患者的预后进行比较。所有手术均在局部麻醉下门诊进行。结果：15名神经源性女性和91名非神经源性女性接受了治疗。在神经源性患者中，73.3%（11/15）的患者在3个月时报告了改善（PGI-I）。4例出现短暂性急性尿潴留（27%）。3例患者需要自行置管；2例术后保持不变，1例改善。在中位7个月的随访后，66.7%的神经源性患者保持干燥或表现出改善。两组间并发症发生率比较（20% vs 27%, p=0.50）。3个月的治疗效果也相似（66.7%的神经源性改善或非常改善，63.3%的非神经源性改善，p=0.88）。结论：Bulkamid®在神经源性和非神经源性SUI女性患者中具有相当的安全性和有效性。然而，自我导尿对患者的益处仍不确定，需要进一步调查。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

The French journal of urology

自引率

0.00%

发文量